Literature DB >> 7053378

Heparin with two binding sites for antithrombin or platelet factor 4.

R E Jordan, L V Favreau, E H Braswell, R D Rosenberg.   

Abstract

A new, highly discriminating affinity chromatographic technique has been developed which employs antithrombin and concanavalin A-Sepharose to fractionate heparin species of all molecular sizes. This methodology is able to subdivide the active mucopolysaccharide pools of molecular weight 6,000 to 8,000 (LMW) or 18,000 to 22,000 (HMW) into various species with descending affinities for antithrombin as well as decreasing anticoagulant potencies. The upper 10% of these two pools, either LMW or HMW highly active heparin, appears to be relatively homogeneous with respect to interactions with antithrombin and possessed anticoagulant potencies of 350 units/mg and 731 units/mg, respectively. The HMW highly active heparin has been examined by analytic ultracentrifugation. It exhibited a charge-connected weight-average molecular weight of 22,000 +/- 2,000 with minimal size heterogeneity. The stoichiometries of interaction of antithrombin and platelet factor 4 with HMW highly active heparin as determined by fluorescence spectroscopy indicated that 2 molecules of either protein are able to bind to 1 molecule of the mucopolysaccharide. These studies also reveal that the binding of antithrombin to HMW highly active heparin is characterized by KDISSHAT = 5.0 X 10(-8) M and KDISSHAT2 = 1.0 x 10(-7) M, respectively. The avidity of platelet factor 4 for HMW highly active heparin could not be quantitated but appears to be at least 10 to 100 times greater than that of antithrombin for mucopolysaccharide.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7053378

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Cell mutants defective in synthesizing a heparan sulfate proteoglycan with regions of defined monosaccharide sequence.

Authors:  A L De Agostini; H K Lau; C Leone; H Youssoufian; R D Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Polyelectrolyte charge corrected molecular weight and effective charge by sedimentation.

Authors:  E H Braswell
Journal:  Biophys J       Date:  1987-02       Impact factor: 4.033

3.  Interaction of heparin with two synthetic peptides that neutralize the anticoagulant activity of heparin.

Authors:  Jing Wang; Dallas L Rabenstein
Journal:  Biochemistry       Date:  2006-12-26       Impact factor: 3.162

4.  Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum.

Authors:  K T Preissner; L Zwicker; G Müller-Berghaus
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

Review 5.  Clearance of thrombin in vivo: significance of alternative pathways.

Authors:  T H Carlson
Journal:  Mol Cell Biochem       Date:  1986-08       Impact factor: 3.396

Review 6.  The role of vitronectin as multifunctional regulator in the hemostatic and immune systems.

Authors:  K T Preissner
Journal:  Blut       Date:  1989-11

7.  Physicochemical characterization of human S-protein and its function in the blood coagulation system.

Authors:  K T Preissner; R Wassmuth; G Müller-Berghaus
Journal:  Biochem J       Date:  1985-10-15       Impact factor: 3.857

8.  Identification and characterization of PF4varl, a human gene variant of platelet factor 4.

Authors:  C J Green; R S Charles; B F Edwards; P H Johnson
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

9.  Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro.

Authors:  A L Stone; D J Melton; M S Lewis
Journal:  Glycoconj J       Date:  1998-07       Impact factor: 2.916

10.  Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.

Authors:  D A Lane; J Denton; A M Flynn; L Thunberg; U Lindahl
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.